NRIX•benzinga•
Nurix Therapeutics Says FDA Clears IND for IRAK4 Degrader GS-6791/NX-0479, Enabling Initiation Of Phase 1 trial, Which Is Expected To Begin in Q2 2025
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 17, 2025 by benzinga